ストックスクリーナーアプリを入手
74.90
2.39%
1.75
アフターアワーズ：
75.80
0.90
+1.20%
Nektar Therapeutics (NKTR) 最新ニュース
Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema - Stocktwits
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics R&D chief sells $397,670 of common stock - Investing.com
Form 4 Nektar Therapeutics For: 2 July By Investing.com - Investing.com Nigeria
Nektar Therapeutics R&D chief sells $397,670 of common stock By Investing.com - Investing.com UK
Nektar Therapeutics Stock Climbs As Immunology Sentiment Improves - timothysykes.com
How Nektar Therapeutics’ Broad FTSE Russell Index Inclusion Will Impact Nektar Therapeutics (NKTR) Investors - simplywall.st
Jonathan Zalevsky (NKTR) sells 5,737 shares via 10b5-1 plan - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therap - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Investors to Reach Out - ACCESS Newswire
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Index - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2500 Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Value Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Index - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000 Value Benchmark - marketscreener.com
Nektar Therapeutics Actuals & Estimates (NASDAQ:NKTR) - TradingView
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000 Index - marketscreener.com
Price to sales forward of Nektar Therapeutics – SWB:ITH0 - TradingView
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Price to earnings forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Enterprise value to EBITDA forward of Nektar Therapeutics – DUS:ITH0 - TradingView
Price to book forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Enterprise value to EBIT forward of Nektar Therapeutics – DUS:ITH0 - TradingView
Enterprise value to revenue forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Price to sales forward of Nektar Therapeutics – DUS:ITH0 - TradingView
Nektar Therapeutics Company Profile & Introduction - Moomoo
NKTR Forecast — Price Target — Prediction for 2027 - TradingView
A419UB Forecast — Price Target — Prediction for 2027 - TradingView
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year - AOL.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - Stockhouse
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - Yahoo Finance
Nektar Therapeutics (NKTR) Institutional Confidence - TradingKey
Nektar Therapeutics chief R&D officer sells $336,211 in stock - Investing.com UK
Nektar Therapeutics chief R&D officer sells $336,211 in stock By Investing.com - Investing.com Nigeria
Form 4 Nektar Therapeutics For: 22 June By Investing.com - Investing.com South Africa
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-21 | Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Certain Performance Restricted Stock Units of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
Certain Common Stock of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
NKTR Technical Analysis & Stock Price Forecast - Intellectia AI
NKTR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Nektar Therapeutics CEO Robin Howard W sells $1.2m in stock - Investing.com UK
Nektar Therapeutics CEO Robin Howard W sells $1.2m in stock By Investing.com - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
NKTR News | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):